You're signed outSign in or to get full access.
About
Jingqing Zhang is a Research Associate at RTW Investments, LP, based in Scarsdale, NY, where she focuses on scientific due diligence and research coverage for areas including cardiometabolic, cardiovascular, and eye diseases. She plays a key role in evaluating and supporting the firm's investment in biotechnology assets and therapeutics, with significant responsibility for due diligence on portfolio companies such as JIXING.
Before joining RTW Investments, Dr. Zhang was Associate Director of Strategic Portfolio Management and previously a Senior Business Development Manager at GenScript, leading business development and strategy efforts. Her earlier career includes senior R&D and operational roles at venture-backed startups, with a track record of successful company exits through acquisition.
She holds a Ph.D. in Chemical Engineering (with a minor in Economics and Business) from the Massachusetts Institute of Technology, where her research centered on biological applications for fluorescent nanomaterials, and a B.S. in Chemical Engineering from Tsinghua University. Dr. Zhang’s expertise spans strategic evaluation of biotech opportunities and translational science, contributing to RTW’s leadership in biopharmaceutical and medical technology investing.
Career History
| Organization | Role | Date Range | Details |
|---|---|---|---|
| RTW Investments, LP | Research Associate | Oct 2021 to Present | — |
| RTW Investments, LP | Research Team Intern | Jun 2021 to Oct 2021 | — |
| GenScript | Assoc. Director, Strategic Portfolio Management, Previously Sr. BD Mgr. | Jul 2019 to Jun 2021 | — |
| Aebeca, Inc. (Co. acquired in 2018) | Owner and President | Aug 2017 to Dec 2018 | — |
| Nima (Co. acquired 2020) | Director of R and D, Previously Lead Scientist | Mar 2014 to Aug 2017 | — |
| AgaMatrix, Inc | Scientist | Jan 2013 to Feb 2014 | — |
| Massachusetts Institute of Technology | Research Assistant, PhD Thesis | Sep 2007 to Dec 2012 | - Synthesized and optimized a sensor platform for detecting cardiac troponin in human serum - Developed polymer-nanoparticle complexes for selective detection of multiple small molecules; led a cross-... |
| MIT Voluntary Consulting Club | Strategy Consultant | Jun 2008 to Nov 2012 | Planned and disseminated strategic consulting services for various companies in various growth stages. |
| Wolf, Greenfield & Sacks, P.C. | Patent Law Intern | Jan 2010 to Jan 2010 | — |
| Tsinghua University | Research Assistant, Undergraduate Thesis | Aug 2006 to Jun 2007 | - Developed a novel membrane protein assay for evaluation of evolved variants - Designed and performed multiple rounds of directed evolution of a Z. mobilis xylose transporter |
Education
Massachusetts Institute of Technology
Ph.D., Chemical Engineering (Minor: Economics and Business)
2007 — 2012
Tsinghua University
B.S., Chemical Engineering
2003 — 2007
Skills & Expertise
Others at RTW Investments, LP (14)
| Name | Role | Location |
|---|---|---|
 | Partner | New York, NY , United States |
 | Head Trader | New York, NY , United States |
N Naveen Yalamanchi | Partner | New York, NY , United States |
R Robert Rapaport | Research Analyst | New York, NY , United States |
 | Senior Analyst | New York, NY , United States |
 | Research Analyst | NY , United States |
J Jeffrey Wang | Research Analyst | New York, NY , United States |
 | Partner | New York, NY , United States |
L Lauren Lee | Research Analyst | New York, NY , United States |
L Luc Ghaleb | Associate | New York, NY , United States |
Similar Fund Managers
| Name | Role | Fund | Location |
|---|---|---|---|
A Andrey Belov | Research Analyst | Cramer Rosenthal Mcglynn LLC | Stamford, CT , United States |
B Brian Harvey | Equity Portfolio Manager | Cramer Rosenthal Mcglynn LLC | United States |
